{
  "metadata": {
    "title": "Diffusion Changes in Hippocampal Cingulum in Early Biologically Defined Alzheimers Disease",
    "authors": [
      "Qianyun Chen",
      "Jill Abrigo",
      "Min Deng",
      "Lin Shi",
      "Yi-Xiang Wang",
      "Professor Winnie Chiu",
      "Room Wing Chu"
    ],
    "abstract": "Background: Diagnosis of Alzheimers disease (AD) was recently shifted from clinical to biological construct to reflect underlying neuropathological status, where amyloid deposition designated patients to the Alzheimers continuum, and additional tau positivity represented AD. Objective: To investigate white matter (WM) alteration in the brain of patients in the Alzheimers continuum. Methods: A total of 236 subjects across the clinical and biological spectra of AD were included and stratified by normalabnormal (-) amyloid (A) and tau (T) status based on positron emission tomography results, yielding five groups: A-T-cognitively normal (CN), AT-CN, AT CN, AT mild cognitive impairment, and AT AD. WM alteration was measured by diffusion tensor imaging (DTI). Group differences, correlation of DTI measures with amyloid and tau, and diagnostic performance of such measures were evaluated. Results: Compared with A-T-CN, widespread WM alteration was observed in the Alzheimers continuum, including hippocampal cingulum (CGH), cingulum of the cingulate gyrus, and uncinate fasciculus. Diffusion changes measured by regional mean fractional anisotropy (FA) in the bilateral CGH were first detected in the AT CN group and associated with tau burden in the Alzheimers continuum (p  0.001). For discrimination between AT CN and A-T-CN groups, CGH FA achieved accuracy, sensitivity, and specificity of 74, 58, and 78 for right CGH and 57, 83, and 47 respectively for left CGH. Conclusion: WM alteration is widespread in the Alzheimers continuum. Diffusion alteration in CGH occurred early and was correlated with tau pathology, thus may be a promising biomarker in preclinical AD.",
    "publication_date": ""
  },
  "content": {
    "INTRODUCTION": {
      "text": "Alzheimers disease (AD) is characterized by two hallmarks, namely, amyloid- (A) and neurofibrillary tangles composed of phosphorylated tau, which occurs for years prior to the presentation of clinical symptoms. Detecting AD-related pathological changes during the asymptomatic stage is important not only to understand disease mechanisms and progression but also to allow potential intervention and facilitate recruitment in clinical trials 1. Currently, A and tau can only be confirmed on postmortem examination 2, which has driven research impetus for the identification of in vivo imaging biomarkers to aid in AD diagnosis. Measures for in vivo A and tau detection include positron emission tomography (PET) and cerebrospinal fluid (CSF) via lumbar puncture. However, the widespread use of these methods is hindered because of the limited availability of radioactive tracers, expensive cost, and inherent invasiveness. Structural brain imaging may show hippocampal volume loss, but this occurs in the late stage of the disease and is not specific to AD, as it can also be age-related and present in non-AD forms of dementia 3.\nWhite matter (WM) abnormalities are also commonly present among patients with AD and may be a sign of an early neuropathologic event 4. Diffusion tensor imaging (DTI) studies revealed WM demyelination and axonal loss in mild cognitive impairment (MCI) and preclinical AD 5. DTI is an MRI technique that quantifies the magnitude and directionality of the molecular diffusion of water along axonal tracts, allowing the assessment of WM integrity 6. Diffusion in normal axons tends to be limited and parallel to tracts, whereas diffusion in damaged WM exhibits lower fractional anisotropy (FA) and higher mean diffusivity (MD). Results from DTI studies show that altered WM tracts are widespread at the stages of MCI and AD 7 in specific regions related to cognitive decline 8, and in the hippocampal cingulum, corpus callosum, and fornix 8910. Changes in WM have also been reported to precede symptom onset 11, and may be linked to deposition of A 12,13 and tau 6,14,15, suggesting their early involvement in the course of AD. These findings lend support to the notion that WM changes measured by DTI could provide useful information for clinical diagnosis of patients with AD.\nApproximately 10 to 30 of clinically diagnosed AD dementia do not display AD pathologic change at autopsy 16, while 30 to 40 of cognitively unimpaired elderly persons have AD pathology at autopsy 17. To better reflect underpinning neuropathology, the diagnosis of AD has been shifted from clinical to biological in the research setting. Only individuals with abnormal A deposits are considered to be in the Alzheimers continuum, which is further divided into two phases: Alzheimers pathologic change individuals with abnormal A but normal tau biomarker (AT-) and AD individuals with abnormal A and tau biomarkers (AT) 18. It remains unclear how WM changes in the Alzheimers continuum with A, tau, and cognitive status considered. The main objective of the present study was to determine the patterns of WM alterations on DTI in subjects within the Alzheimers continuum at different clinical stages. The second objective was to explore the association of WM microstructural changes with A and tau burden within the Alzheimers continuum. The third objective was to explore the diagnostic performance of regional mean FA values derived from DTI in the preclinical stage of AD defined by the biological markers.",
      "subsections": {}
    },
    "Subjects": {
      "text": "All data was acquired from the Alzheimers Disease Neuroimaging Initiative 3 database (ADNI 3) (http:adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessments can be combined to assess the progression of MCI and early AD. ADNI includes men and women aged 55-90 years across cognitively normal (CN), MCI, and AD dementia groups. The clinical diagnosis was given according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimers Disease and Related Disorders Association (NINCDS-ADRAD) 19.\nFor the current study, participants at various clinical stages who underwent T1-weighted MRI, DTI, AV45 Florbetapir PET, and AV1451 Flortaucipir PET at ADNI3 baseline were included. Demographic information such as age, sex, years of education, Clinical Dementia Rating (CDR), Mini-Mental State Exam (MMSE), and clinical diagnosis were recorded.",
      "subsections": {}
    },
    "Biomarker group classification and PET analysis": {
      "text": "According to the National Institute on Aging and Alzheimers Association (NIA-AA) 2018 research framework 18, A determines if individuals have Alzheimers pathologic change (AT-), and both A and pathologic tau are required for a diagnosis of AD (AT). In this study, we followed the NIA-AA recommendations and selected subjects mainly by A and T biomarker profiles. Clinical diagnosis was used for staging severity. In addition, we hypothesized that white matter diffusion change occurs at an early stage, therefore subjects were categorized into the following groups: 1) CN subjects with normal A and tau (A-T-CN); 2) CN subjects with abnormal A but normal tau (AT-CN); 3) CN subjects with abnormal A and tau (AT CN); 4) MCI with abnormal A and tau (AT MCI); and 5) dementia with abnormal A and tau (AT AD).\nA and tau status were determined using AV45 florbetapir and AV1451 flortaucipir PET values provided by the University of California, Berkeley. The AV45 florbetapir PET was used to assess global A load. The mean standard uptake value ratio (SUVR) on AV45 PET was calculated from the cortical summary regions-of-interest (ROIs), including frontal, anteriorposterior cingulate, lateral parietal, and lateral temporal regions, with whole cerebellum as reference region. A cut-off value of 1.11 was applied to determine A positivity (A) 20. The AV1451 Flortaucipir PET SUVR values were used to quantify tau burden in the AD signature regions. Briefly, a size-weighted mean Flortaucipir SVUR was calculated in temporal meta-ROI including amygdala, entorhinal, fusiform, inferior temporal and middle temporal gyri, and normalized by inferior cerebellar gray matter. Tau positivity (T) was thresholded at an SUVR of 1.23 21.",
      "subsections": {}
    },
    "Structural MRI acquisition and analysis": {
      "text": "Image protocols were standardized across ADNI study sites. 3D T1-weighted volumetric sequences were acquired with the following parameters: echo time (TE)  2.98 ms, repetition time (TR)  2300 ms, inversion time  900ms, flip angle  10  , field of view (FOV)  208  240  256 mm 3 , acquired resolution  1  1  1 mm 3 . The details of the MRI parameters can be found at http:adni.loni. usc.edumethodsdocumentsmri-protocols.\nT1-weighted images were corrected for head motion and intensity inhomogeneity, followed by removal of non-brain tissue using the pipeline implemented in Freesurfer version 7.1 (http:surfer.nmr.mgh.harvard.edu). Skull-stripped volumes were visually inspected and manually modified when needed. Hippocampal volume (HV) and estimated total intracranial volume (eTIV) were derived from Freesurfer output. HV was normalized by eTIV using the following formula 14:\nAdjusted HV  raw HVb(eTIVmean eTIV)\n(1) where b indicates the regression coefficient when HV is regressed against eTIV.\nConsidering that white matter hyperintensities (WMH) shown on T2 FLAIR images are possible factors associated with vascular disease and may influence DTI measures on WM 22, we controlled for WMH volumes in the statistical analysis. WMH volumes were obtained from ADNI, which was estimated with a modified Bayesian probability structure based on the method of histogram fitting. Briefly, the likelihood estimates of each image were calculated through histogram segmentation and thresholding. Then, along with WMH priors (which were estimated from more than 700 individuals) and tissue constraints, the probabilities were thresholded at 3.5 standard deviations above the mean to create a binary WMH mask. Finally, the mask was back-transformed to native space for volume calculation. The WMH volumes were available for all included subjects.",
      "subsections": {}
    },
    "DTI acquisition and analysis": {
      "text": "Six b 0 images and 48 diffusion-weighted DWI scans at b value  1000 smm 2 were acquired at 2  2  2 mm 3 resolution (GE: time repetition, 7800 ms; flip angle, 90  ; time echo, 55-62 ms; field of view, 232  232  138 mm. Siemens: time repetition, 7200-9600 ms; time echo, 56-82 ms; flip angle, 90  ; field of view, 232  232  160 mm 3 ). For each subject, raw DWI volumes were first corrected for head motion and eddy-current distortions with the eddy correct tool from the FMRIB software library (FSL) (http:www.fmrib.ox.ac.ukfsl). b vectors were rotated accordingly 23. All nonbrain tissues were removed from diffusion-weighted images using the FSLs Brain Extraction Tool. Skullstripped b 0 images were registered to their respective corrected T1-weighted scans based on white-matter boundaries using the FSLs epi reg tool. The resulting 3D transformation matrices and deformation fields were applied to the remaining DWI volumes. Lastly, a single diffusion tensor was fitted at each voxel in the brain by using FSLs DTIFIT program, and the diffusion tensor eigenvalues obtained were used to calculate FA and MD maps. All processed images were visually inspected for quality control. Thirtyfive images were excluded from further analysis due to excessive distortion artifacts.\nTo derive DTI measures from specific WM tracts, the Johns Hopkins University-International Consortium of Brain Mapping (JHU-ICBM)-DTI atlas 24 containing 48 WM tracts was used. The list of tracts in the atlas is presented in the Supplementary Table 1. The DTI atlas was first linearly and then non-linearly registered to each individuals FA maps using FSLs registration tools 25,26. The derived deformation field was then applied on the WM label to obtain WM ROIs in the individual spaces. Voxels with FA value 0.2 were excluded from the ROIs. The WM ROI was superimposed on FA and MD maps separately to extract mean values.",
      "subsections": {}
    },
    "Statistical analysis": {
      "text": "The normality of continuous variables was first examined by Shapiro-Wilk test in which the assumption of normality was violated. WMH was log-transformed for subsequent analysis due to its skewness. Group comparisons for continuous variables with skewed distribution were performed using Kruskal-Wallis test along with Mann-Whitney U test for post hoc comparison; otherwise, analysis of variance followed by Scheffes tests was conducted for normally distributed variables. Chi-square test was employed to analyze categorical variables.\nTo evaluate the group difference in diffusion metrics of 48 atlas-based tracts, analysis of covariance (ANCOVA) was performed with control of age, sex, years of education, and WMH volumes. Bonferroni method (p  0.0548) was used to adjust for false-positive results in multiple comparisons of 48 atlas-based regions of interest. If the ANCOVA results were significant, post hoc comparisons were then performed with the Bonferroni method.\nTo assess the association of DTI measures with global A load and tau burden in the temporal meta-ROI, we formulated a regression model with FAMD value as dependent variable, while A and tau as well as four covariates (age, sex, years of education, and WMH volume) were used as independent variables. Correlation of DTI measures with HV was also assessed. For these analyses, we verified the normal distribution of the residuals, the absence of heteroscedasticity, and the lack of multicollinearity between the variables, which was determined using a variance inflation factor below 10. A regression model was built in each of the following cohorts: (i) the Alzheimers continuum group (all groups except for A-T-CN group), (ii) the A-T-CN group, (iii) the AT-CN group, and (iv) the AT CN group. The p value was adjusted for multiple comparisons with the Bonferroni method (p  0.054).\nTo evaluate the diagnostic performance of DTI measures, we analyzed the receiver operating characteristic (ROC) curves. We focused on detecting AD pathology in subjects without presenting clinical symptoms, so we performed the following classification among CN subjects: 1) A-T-CN versus AT-CN; 2) A-T-CN versus AT CN; 3) AT-CN versus AT CN. HV was included for comparison as it is the most established biomarker of AD 3. Diagnostic performance was evaluated using the area under the ROC curve (AUC). The optimal cutoff for positivity was determined using the Youden Index 27. Accuracy, sensitivity, and specificity were calculated based on the derived cutoff value. DeLongs test 28 was performed to compare differences in the performance of various diagnostic metrics. All statistical analyses were performed using SPSS 26.0 (Armonk, NY). Statistical tests were two-sided, with a significance level set to p  0.05.",
      "subsections": {}
    },
    "Group comparisons": {
      "text": "For FA, significant differences across five groups were found in the tracts of fornix, hippocampal cingulum (CGH), cingulum of the cingulate gyrus (CGC), and uncinate fasciculus (UF) after controlling for age, sex, years of education, and WMH volume (fornix, F(4, 227)  6.84, p  0.001; right CGH, F(4, 227)  9.47, p  0.001; left CGH, F(4, 227)  12.38, p  0.001; right CGC, F(4, 227)  5.58, p  0.001; left CGC, F(4, 227)  5.50, p  0.001; right UF, F(4, 227)  5.82, p  0.001; left UF, F(4, 227)  5.50, p  0.001). In general, FA in CN groups was higher than that in MCI and AD groups. Specifically, compared with the A-T-CN group, AT AD group showed lower FA values in the tracts of fornix, CGH, CGC, and UF (all with p  0.001), while the AT MCI group showed lower FA values in the bilateral CGH tract (all with p  0.001). The AT AD and AT MCI groups showed lower FA in the tracts of fornix, CGH, CGC and UF than the AT-CN group, with p  0.001 for the AT AD group and p  0.05 for the AT MCI group. The FA was significantly reduced between AT CN and AT AD for the tracts of fornix, CGH, CGC, and UF (all with p  0.01) and between AT MCI and AT AD for the tracts of bilateral CGH, CGC, and UF (all with p  0.05). Among three CN groups, both right and left CGH FA showed a significant difference between A-T-CN and AT CN groups, and left CGH FA presented a significant decrease in AT CN compared with AT-CN group (Fig. 1).\nRegarding MD, significant differences across five groups were found in the tracts of genu of the corpus callosum (GCC), body of the corpus callosum (BCC), splenium of the corpus callosum (SCC), CGC, CGH, superior longitudinal fasciculus (SLF), and UF (all with p  0.001). In general, MD in the MCI and AD groups were higher than that in the CN groups and was comparable among CN groups. Specifically, compared with the A-T-CN group, both AT AD and AT MCI groups showed higher MD in the tracts of GCC, BCC, SCC, CGC, CGH, SLF, and UF. Compared with the AT-CN group, the AT AD group showed higher MD in the tracts of GCC, BCC, SCC, CGC, CGH, SLF, and UF (all with p  0.001), while the AT MCI group showed higher MD in these tracts (all with p  0.05) except for left UF (p  0.68). Compared with the AT CN group, the AT AD group showed higher MD in the tracts of GCC, BCC, SCC, CGC, CGH, SLF, and UF (all with p  0.001), while the AT MCI group showed higher MD in the tracts of BCC (p  0.04), GCC (p  0.03), right CGC (p  0.01), bilateral CGH (all with p  0.01), bilateral SLF (all with p  0.02), and right UF (p  0.01). No significant difference was found among the three CN groups.",
      "subsections": {}
    },
    "Association of DTI measures in CGH with global AÎ² load, tau burden in the temporal meta-ROI, and HV": {
      "text": "Bilateral CGH was the only tract that showed FA changes among CN groups, and consistently showed lower FA in the AT CN, AT MCI, and AT AD groups when compared with the A-T-CN group. In this regard, we further investigated",
      "subsections": {}
    },
    "Diagnostic performance of CGH FA in preclinical AD": {
      "text": "Table 3 shows the results of ROC analysis of FA in right and left CGH and HV to discriminate between A-T-CN, AT-CN, and AT CN groups. The discrimination between A-T-CN and AT CN groups was achieved by right and left CGH FA (p  0.001), with the AUCs of 0.69 for right CGH FA, and 0.68 for left CGH FA. Specifically, right CGH FA achieved 74 of accuracy, 58 of sensitivity and 78 of specificity, while left CGH FA had 57 of accuracy,",
      "subsections": {}
    },
    "DISCUSSION": {
      "text": "This study aims to describe WM microstructural alteration on DTI in the Alzheimers continuum defined by A deposition. Decreased FA and increased MD were observed across the Alzheimers continuum, with the earliest alteration occurring in CGH at the CN stage with positive A and tau status. The alteration of the DTI measures in the Alzheimers continuum was correlated with tau but not with A, suggesting that WM change may reflect underlying tau pathology. Furthermore, FA change in bilateral CGH allowed for the discrimination between CN subjects with and without AD pathologies. Our results encourage further investigation on diffusivity changes in the CGH region in preclinical AD.\nDiffusion alteration in widespread WM tracts was observed in AT MCI and AT AD groups, including fornix, SLF, UF, CGC, and CGH. The findings are consistent with the previous meta-analysis in studying WM alterations in MCI, which found reliable FA and MD alterations in the above-mentioned tracts 29,30. Our study reinforces such alterations in WM in clinically diagnosed AD but also in biologically defined patients where A and tau status are considered. Such alterations occur in cumulative patterns with increasing cognitive impairment and increasing A and tau load. Among the three CN groups, most tracts showed a trend of increased FA and decreased MD in the AT-CN group, followed by a decreased FA and increased MD in the AT group. However, the differences between groups did not reach a statistically significant level. A diffusion kurtosis imaging study demonstrated that subjects with intermediate A load displayed more restricted diffusion compared with subjects with either low or high A load, indicating a nonmonotonic trend in diffusion restriction in early A accumulation 31. Our study further showed that the decreased diffusion restriction occurred at the stage when both A and tau reached a high level. Hence, a high amount of tau might account for the diffusion alteration in the later stage of A accumulation. A presence may strengthen the association between tau and WM alterations 14 and indirectly accelerate WM degradation in the long run 32.\nCGH is the only tract that presented FA alteration in the CN stage between AT CN and A-T-CN groups, and the FA consistently decreased in AT MCI and AT AD groups. Our results are in line with previous studies which found altered CGH diffusion in subjects with AD 33, MCI 33, and subjective cognitive decline 9. CGH is the hippocampal formation part of the cingulum, thus its integrity may be partly linked to the integrity of the hippocampus. In addition, CGH is a major pathway of the limbic system, and it connects the hippocampus to the cingulate gyrus 34. It was reported that CGH diffusivity can predict tau burden in the downstreamconnected posterior cingulate cortex in A-positive subjects 14. Therefore, diffusion alteration in CGH could be a potential biomarker in detecting and monitoring the early accumulation of AD pathology. A significant correlation was observed between diffusion measures and tau but not with A in the Alzheimers continuum, suggesting that tau may be a predominant factor that affects diffusion in the course of AD. Our findings on DTI correlation with tau is consistent with previous literature. The association with tau has been reported in the AD-signature region 15, and increased MD has been shown to correlate with neurofibrillary tangle at autopsy 6. Abnormal tau hyperphosphorylation leads to decreased microtubule binding, destabilizes microtubules, and results in axonal integrity loss 15, leading to a lower FA and higher MD value. Thus, DTI measures may be a potential biomarker in monitoring the accumulation of tau pathology. As for A, inconsistent findings were reported on the correlation of WM alteration with A. Along with others 6,15, we did not observe the correlation of diffusion measures with global A in the mixed cohort of cognitively unimpaired and impaired subjects, while the correlation was reported by other studies at global 35 and regional levels in terms of the cingulum, corpus callosum 13, and UF 36 in the cognitively unimpaired subjects. A accumulates early in the course of AD and is assumed to reach a plateau before the onset of cognitive symptoms 37, so the correlation is anticipated in the asymptomatic stage. However, we did not observe the correlation in the CN groups as well. A possible explanation for the inconsistency is that the diffusion change in CGH may correlate with A in the regions connected by the CGH rather than global A measured in this study. Further, a potential non-monotonic association 13,35 may also not be revealed by our statistical analysis.\nRight and left CGH FA allow discrimination between A-T-CN and AT CN groups, and left CGH FA achieved 83 sensitivity and right CGH FA achieved 78 specificity. This finding may suggest that FA changes in the left CGH occur earlier than that in the right CGH. However, the overall diagnostic performance was not high because all the AUC values did not exceed 0.7. In addition, a wide range of AUC may not be suitable for its clinical use. Although a distinct difference in FA in CGH between subjects with and without AD pathology was detected at the CN stage, the differences may not allow for accurate discrimination at the individual level. FA in CGH has been studied for discrimination. One study used FA from all voxels within the CGH ROI to discriminate CN, MCI, and AD subjects with a support vector machine, and achieved average accuracies of 87 between AD and controls and 83 between AD and MCI 34. Hence, FA measurement in CGH has potential to assist in AD diagnosis.\nThis study has several limitations. First, as a crosssectional study design was used, this work cannot assume that a subject with a certain level of AD pathology is temporally similar in clinical manifestation to another subject with the same level of pathology. Future longitudinal studies could better elucidate microstructural changes in CGH with increasing AD pathology over time. Second, we did not further classify subjects based on neurodegeneration due to the small sample size. Neurodegeneration may correlate more with diffusion change than A 10. We controlled the neurodegeneration effect as indexed by hippocampal volume in the analysis. Further study may explore the complete spectrum of biologically defined AD with additional neurodegeneration factor added. Third, the grouping is limited to the expected progression of classic pure AD through the biomarker schema, of which clinical MCI or dementia do not occur until A, T, and neurodegeneration biomarkers are abnormal so the cognitive deficit is attributable to AD pathologies alone. However, other biomarker combinations do occur in the clinical MCI and dementia stage and may indicate other processes. Future study may explore the diffusion changes in MCI and dementia subjects with biomarker combinations such as AT-. Fourth, with the ROI-based analysis adopted, the derived diffusion metrics largely rely on the accuracy of image registration. Advanced DTI analysis methods, such as tractometry, could derive fiber-specific diffusion metrics 36, which may in turn improve the diagnostic performance of diffusion metrics in CGH.\nIn summary, this study investigated WM alteration on DTI in the Alzheimers continuum. Decreased FA in the hippocampal cingulum was first detected in CN subjects with high levels of A and tau burden and allowed for the discrimination from pathology normal subjects. Our results encourage further investigation on diffusivity changes in the CGH region in preclinical AD.",
      "subsections": {}
    }
  }
}